HCV Drug Resistance: Regulatory Perspective
|
|
- Anthony Crawford
- 6 years ago
- Views:
Transcription
1 HCV Drug Resistance: Regulatory Perspective Patrick Harrington, PhD Senior Clinical Virology Reviewer Division of Antiviral Products, FDA/CDER 2016 HIV and Hepatitis Clinical Pharmacology Workshop Washington, D.C. Disclosures: none 1
2 Disclaimer The views expressed in these slides are those of the presenter and do not necessarily represent official policy of the Food and Drug Administration. 2
3 Presentation Outline Review of basic HCV antiviral drug resistance concepts Impact of HCV polymorphisms on treatment efficacy in DAA clinical trials, and considerations for pre-treatment resistance testing Perspective on re-treatment for DAAexperienced patients 3
4 HCV Drug Resistance Basic Concepts and Definitions (1) Baseline polymorphism Major natural genetic variant that is present in the viral population of a minority of infected individuals. Major means detectable by Sanger population sequencing or at a comparable sensitivity level by Next Generation Sequencing (generally at least 10-15% of sequence reads). Not to be confused with a low abundance minority variant present in viral quasispecies. Treatment-emergent substitution Amino acid change that emerged or became enriched in the viral population with treatment. 4
5 HCV Drug Resistance Basic Concepts and Definitions (2) Resistance-associated polymorphism or substitution Amino acid variant that is associated with treatment failure with a DAA or regimen, or associated with phenotypic resistance to a DAA. The presence of a resistance-associated polymorphism or substitution in a viral population does not necessarily mean a drug is ineffective. Drug resistance barrier Describes the potential for drug resistance selection. Generally reflects the number and type of viral genetic changes that confer resistance to a clinically relevant concentration of the drug. 5
6 Drug Resistant Virus Often Pre-Exists (Example from Rong, Perelson et al., 2010) HCV: virions produced each day in an individual. Replication error rate: 10-5 to 10-4 per nucleotide (i.e., 0.1 to 1 change per genome per round of replication). Do the math all possible single and combinations of double nucleotide mutant viruses preexist in the quasispecies before treatment, and additional mutations arise early during therapy. Many early generation HCV DAAs have a low barrier to resistance: impacted by single amino acid changes in the target protein. Drug resistant virus preexists and is rapidly selected by monotherapy. Combinations of drugs with non-overlapping resistance mechanisms prevent drug resistance selection because they collectively have a higher resistance barrier than the individual drugs. 6
7 Monotherapy with a Low Resistance Barrier Drug Selects for Resistance HCV RNA decline during monotherapy unmasks and enriches drug resistant virus Green=low dose, Pink=mid dose, Purple=high dose Dvory-Sobol et al., AAC 2012 Schiffer et al., Nat Med
8 Examples of Early Low Resistance Barrier IFN-Free DAA Regimens GS Tegobuvir (PI + Non-Nuc) GS Tegobuvir + RBV (PI + Non-Nuc + RBV) Lok et al., NEJM 2012; 366: Zeuzem et al., Hepatology (2012) 55, 3:
9 Highly Effective (>90% SVR Rates) IFN- Free Regimens (HCV Treatment Guidelines Spring 2016) DAA Combination DAA Class(es) Sofosbuvir + RBV NS5B Nuc. Analogue Polymerase Inhibitor 2 Ledipasvir/Sofosbuvir ± RBV Ombitasvir/Paritaprevir/ ritonavir ± Dasabuvir ± RBV Daclatasvir + Sofosbuvir ± RBV Simeprevir + Sofosbuvir ± RBV NS5A Inhibitor/ NS5B Nuc. Analogue Polymerase Inhibitor NS5A Inhibitor/NS3 PI/ NS5B Non-Nuc. Polymerase Inhibitor NS5A Inhibitor/ NS5B Nuc. Analogue Polymerase Inhibitor NS3 PI/ NS5B Nuc. Analogue Polymerase Inhibitor Elbasvir/Grazoprevir ± RBV NS5A Inhibitor/NS3 PI 1, 4 Genotype Coverage 1, 4, 5, 6 1, 4 1, 2, 3 1 9
10 Impact of HCV Polymorphisms on Efficacy of DAA-based Regimens 10
11 Impact of HCV Polymorphisms on Efficacy of DAA-based Regimens Many IFN-free DAA combinations can be impacted by the presence of polymorphisms in drug target genes. The clinical impact of HCV polymorphisms is influenced by other factors that also impact treatment efficacy, such as patient disease characteristics (e.g., cirrhosis), the activity and resistance barrier for other drugs in the regimen, and treatment duration. The presence of a DAA resistance-associated polymorphism does not preclude the use of the DAA. Optimized/intensified DAA regimens (e.g., additional DAAs, ribavirin, and/or longer treatment duration) can overcome the presence of polymorphism(s) in drug target genes. 11
12 To screen or not to screen for polymorphisms... Favoring Screening Clear impact on efficacy Significantly impacts U.S. population Assay commercially available Reasonable alternative treatment options available (including waiting) Resistance consequences of failure Limited or no re-treatment options Clinical consequences of failure Screening Not Necessary No clear impact on efficacy Very low (<<5%) overall virologic failure rates in population No commercially available assay Alternative treatment options not available Minimal resistance consequences of failure Reasonable re-treatment options available Minimal clinical consequences of failure Factors Generally Not Considered Cost Complicating the treatment algorithm 12
13 Resistance testing is relatively simple Response-Guided Therapy Cirrhosis Determination in Trials (e.g.) Afdhal N, Reddy KR, Nelson DR, et al. N Engl J Med 2014;370: Resistance Test Test: NS5A Substitution Detected: Y93H VA boceprevir treatment algorithm 13
14 To screen or not to screen for polymorphisms... Favoring Screening Clear impact on efficacy Significantly impacts U.S. population Assay commercially available Reasonable alternative treatment options available (including waiting) Resistance consequences of failure Limited or no re-treatment options Clinical consequences of failure Screening Not Necessary No clear impact on efficacy Very low (<<5%) overall virologic failure rates in population No commercially available assay Alternative treatment options not available Minimal resistance consequences of failure Reasonable re-treatment options available Minimal clinical consequences of failure Factors Generally Not Considered Cost Complicating the treatment algorithm 14
15 Simeprevir + P/R: GT1a NS3 Q80K D.Deming, FDA Clinical Virology review of simeprevir Key factors that contributed to label recommending screening for Q80K: GT1a Q80K polymorphism substantially reduces efficacy of SMV + P/R High prevalence of Q80K in U.S. (48% of GT1a) Resistance consequences of failure: Emergence of R155K (or others) Boceprevir and telaprevir not impacted and represented alternative treatments 15
16 Simeprevir + Sofosbuvir: GT1a Q80K Sarrazin C., J Hepatol. Q80K associated with reduced efficacy in non-cirrhotic GT1a patients for 8-week duration but not with 12-week duration Longer treatment duration reduces impact of Q80K Q80K associated with reduced efficacy in cirrhotic GT1a patients treated for 12 weeks Disease status influences clinical impact of Q80K 16
17 LDV/SOF: NS5A PMs and Relapse Rates Trial (GT1) Regimen No NS5A PM With NS5A PM ION-3 (tx-naïve) LDV/SOF 8W 4.8% (8/167) 6.3% (3/48) LDV/SOF 12W 1.9% (3/158) 0% (0/56) LDV/SOF + RBV 8W 3% (5/167) 8.2% (4/49) LDV/SOF 12W 2.3% (2/86) 22% (5/23) ION-2 (tx-exp.) LDV/SOF 24W 0% (0/90) 0% (0/19) LDV/SOF + RBV 12W 3.4% (3/89) 4.5% (1/22) LDV/SOF + RBV 24W 0% (0/91) 0% (0/19) L.Naeger, FDA Clinical Virology review of ledipasvir/sofosbuvir Relapse rates -2% to +20% in those with baseline PMs versus those without Greatest efficacy impact associated with use of less intense regimens, presence of multiple key NS5A polymorphisms, and/or presence of polymorphisms that reduce LDV activity by >100-fold (Zeuzem et al., AASLD 2015). Impact of PMs minimized with regimens recommended in labeling: 12 weeks for most patients, 24 weeks for cirrhotic tx-exp.; 8-weeks considered if low BL HCV RNA 17
18 OBV/PTV/r + DSV (GT1a) P.Harrington, FDA Clin. Virology review of OBV/PTV/r+DSV Low estimated impact (~0-8%) of NS3 Q80K or NS5A polymorphisms in Phase 2b/3 trials Label-recommended regimens maximize efficacy for all subjects regardless of baseline polymorphisms: 2-3% VF rate overall for GT1a Recent retrospective analyses showed NS5A polymorphisms and NS3 Q80K did not impact efficacy of label-recommended regimens (Sulkowski et al., CROI 2016) 18
19 Daclatasvir + Sofosbuvir (GT3) Clear impact of Y93H polymorphism Low or no NS5A inhibitor resistance consequence of failure No other major NS5A resistance-associated substitutions emerged in failures who already had the Y93H polymorphism Y93H alone confers >3,000-fold reduction in DCV activity P.Harrington, FDA Clin. Virology review of daclatasvir At the time, assay for screening was not commercially available and alternative treatment options were not ideal. 19
20 Elbasvir/Grazoprevir Impact of NS5A Resistance-Associated Amino Acid Polymorphisms on Efficacy of EBR/GZR ± RBV for HCV GT1a Infected Subjects T. Komatsu, FDA Clin. Virology review of elbasvir/grazoprevir Clear impact of NS5A polymorphisms (present in ~10-12% of GT1a subjects), although impact variable by NS5A position Nearly all virologic failures with these NS5A polymorphisms gained additional treatment-emergent, resistance-associated substitution(s) in NS3 and/or NS5A No signal of virologic failure among subjects w/ or w/o NS5A polymorphisms treated with EBR/GZR + RBV for 16 weeks (small #s w/ polymorphisms, but challenging group) 20
21 EBR/GZR for HCV GT1a: NS5A Polymorphisms Favoring Screening Clear impact on efficacy Significantly impacts U.S. population Assay commercially available Reasonable alternative treatment options available (including waiting) Resistance consequences of failure Limited or no re-treatment options Clinical consequences of failure Screening Not Necessary No clear impact on efficacy Very low (<<5%) overall virologic failure rates in population No commercially available assay Alternative treatment options not available Minimal resistance consequences of failure Reasonable re-treatment options available Minimal clinical consequences of failure Factors Generally Not Considered Cost Complicating the treatment algorithm 21
22 EBR/GZR Label First example where pre-treatment screening for resistance-associated polymorphisms is recommended to guide optimal use of an IFN-free regimen AASLD/IDSA treatment guidelines consistent with prescribing information 22
23 Daclatasvir/Sofosbuvir ± RBV GT1a Impact of NS5A Polymorphisms Population SVR12 with Polymorphism(s) SVR12 without Polymorphism(s) Subjects with Child-Pugh A/B Cirrhosis 1 2/6 (33%) 38/39 (97%) Subjects without Cirrhosis 9/9 (100%) 72/72 (100%) Subjects Post-Transplant 2/2 (100%) 28/29 (97%) 1 No subjects with Child-Pugh C cirrhosis had NS5A resistance polymorphisms P. Harrington Clin. Virology review of daclatasvir Signal that NS5A polymorphisms (same 4 NS5A positions as EBR/GZR) may impact treatment efficacy in HCV GT1a infected subjects with cirrhosis, although very few subjects Additional tx-emergent NS5A and/or NS5B substitutions in 3 of 4 virologic failures Evidence from other trials/populations that DCV-based regimens impacted by NS5A PMs Evidence from other trials that disease status can influence the impact of BL PMs Not a well-supported alternative to EBR/GZR-12W for GT1a compensated cirrhotic patients with NS5A polymorphisms 23
24 Daclatasvir Label (GT1) Not consistent with AASLD/IDSA guidelines for HCV GT1a infected patients with compensated cirrhosis, which recommend a longer DCV/SOF ± RBV duration of 24 weeks irrespective of NS5A polymorphisms ( Alternative regimen ) 24
25 Clinical Relevance of BL Phenotype (?) Baseline phenotypic resistance may be associated with reduced clinical efficacy, but lack of a baseline phenotype does not preclude clinical relevance. Two NS5A examples illustrate relationship between baseline phenotype, clinical impact, and treatmentemergent substitutions Elbasvir/Grazoprevir 12W: GT1a L31M SVR rate: 38% (5/13) 0.5-fold impact in stable replicon assay, 10-fold in transient assay High fold-change according to AASLD/IDSA tx guidelines Daclatasvir/Sofosbuvir 12W: GT3a Y93H SVR rate: 54% (7/13) 3,733-fold impact on activity 25
26 Elbasvir Concentration (nm) Daclatasvir Concentration (nm) ,1 EBR Plasma C24 Phenotypic Impact of Clinically Relevant NS5A Polymorphisms ,1 DCV Plasma C24 0,01 0,01 0,001 GT1a EC50 GT1a EC50 (Serum-Adj) GT1a-L31M EC50 (Serum-Adj) 0,001 GT1a EC50 GT3a EC50 GT3a-Y93H EC50 EBR/GZR treatment failure in GT1a subjects with NS5A PMs associated with additional emergent NS5A substitutions DCV/SOF treatment failure in GT3 subjects with Y93H generally not associated with additional emergent NS5A substitutions
27 Absolute Quantity of HCV Population (log) How can a polymorphism without a clinically relevant phenotype still be clinically relevant? No Resistance PM L31M (Sensitive) No NS3+NS5A resistant virus present NS5A Resistant (L31M + Other Subst) NS5A Resistant + NS3 PI Resistant Wild-type Predominant L31M Predominant What leads to failure 27
28 Re-Treatment Following DAA Failure 28
29 Re-Treatment Following DAA Failure Combination DAA Treatment Outcome Must Address These Challenges: 1. Baseline characteristics that reduced efficacy of 1 st line DAA regimen, such as: Poor IFN/immune status and IL28B unfavorable genotype HCV GT 1a or GT3 High HCV RNA levels Natural drug resistance polymorphisms Advanced disease Poor drug PK Poor adherence or tolerability 2. AND Treatment-emergent DAA resistance (possibly across multiple classes) Any further disease progression or other comorbidities 29
30 Effective Strategies for DAA Re-treatment More potent, non-cross-resistant regimen (e.g., Sofosbuvir + NS5A inhibitor ± RBV in P/R + PI Failures) Intensified regimen (e.g., add RBV or additional DAA, longer duration) Combinations of novel DAAs with activity against DAAresistant viruses: promising efficacy results emerging in DAA failure populations (including NS5A failures) 30
31 Remaining Questions Impact of resistance-associated polymorphisms/ substitutions and need for resistance testing in DAA combination regimen failures Optimal re-treatment for HCV GT3 infected patients who failed an NS5A inhibitor Scope of GT4 and GT6 subtype diversity and impact on DAA efficacy Optimal treatment for patients with advanced cirrhosis +/- resistance-associated polymorphisms/substitutions 31
32 Thanks to the following FDA/DAVP HCV DAA review team members... Clinical Virology Reviewers Damon Deming, PhD Eric Donaldson, PhD Takashi Komatsu, PhD Lalji Mishra, PhD Lisa Naeger, PhD Jules O Rear, PhD, Team Leader Clinical Reviewers Sarita Boyd, PharmD Wendy Carter, DO Sarah Connelly, MD Russ Fleischer, PA-C,MPH, Acting TL Poonam Mishra, MD, Dep. Dir. Safety Adam Sherwat, MD, Team Leader Kim Struble, PharmD, Team Leader Debbie Birnkrant, MD, Division Director Jeffrey Murray, MD, MPH, Deputy Division Director 32
Hepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More informationDavid L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
FORMATTED: 1/3/16 Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? Atlanta, Georgia: October 2, 216 David L. Wyles, MD Chief, Division of Infectious Disease Denver Health
More information10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado FORMATTED: 1/3/16
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationWhat do we need to know about RAVs clinically?
14 th European HIV & Hepatitis Workshop Rome, 25-27 May, 2016 What do we need to know about RAVs clinically? Stefan Zeuzem, MD University of Frankfurt Germany Background Resistance associated variants
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationGenotype 1 Treatment Naïve No Cirrhosis Options
Genotype 1 Treatment Naïve No Cirrhosis Options Elbasvir/Grazoprevir (Zepatier ) x 12 weeks 1 Glecaprevir/Pibrentasvir (Mavyret ) x 8 weeks Ledipasvir/Sofosbuvir (Harvoni ) x 8-12 weeks 2 1 If genotype
More informationCases: Management of Hepatitis C in Prior Treatment Failure
Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationIs HCV drug resistance an issue?
Is HCV drug resistance an issue? 5TH ASIAN CONFERENCE ON HEPATITIS&AIDS NANJING, CHINA 28-29 MAY 2016 FROM BASIC SCIENCE TO CLINICAL PRACTIC Jürgen Kurt Rockstroh Department of Medicine I, University Hospital
More informationVirological tools for hepatitis C: re-treatment and resistance. Joop Arends Will Irving. by author
Virological tools for hepatitis C: re-treatment and resistance Joop Arends Will Irving Disclosures Joop Arends Advisory board: Gilead, Abbvie, Janssen, MSD, BMS (research) grants: Abbvie, BMS, MSD and
More informationClinical Applications of Resistance Stuart C. Ray, MD
Clinical Applications of Resistance Stuart C. Ray, MD Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Training Program Johns Hopkins University School of Medicine Disclosures
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationHepatitis C: Aplicaciones Clínicas de la Resistencia. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña
Hepatitis C: Aplicaciones Clínicas de la Resistencia Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña DAA agents approved or in more advanced stages of clinical
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationStudy Design - GT 1 Retreatment
Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks Eric Lawitz, Steven Flamm, Jenny C. Yang, Phillip S. Pang, Yanni Zhu, Evguenia
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationResistance to DAAs: Real or over-estimated issue? P. Karayiannis
Resistance to DAAs: Real or over-estimated issue? By P. Karayiannis HEPATITIS C VIRION STRUCTURE: LIPO-VIRAL PARTICLE ApoB ApoE VLDL Core RNA Envelope E1 E2 Electron micrograph 9.6 kb HCV genome organisation
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationResistencias & Epidemiología. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña
Resistencias & Epidemiología Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Rapid Evolution of HCV Regimens: Easier to take/tolerate, Short Duration, Pangenotypic,
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationIntroduction to the Impact of Resistance in Hepatitis C
Introduction to the Impact of Resistance in Hepatitis C Sponsored by AbbVie 2/1/2017 Presented by Sammy Saab, MD, MPH, FACG, AGAF, FAASLD February 1 st, 2017 1 AbbVie disclosures This is an Abbvie sponsored
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationFailure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016
Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16 Disclosures Board member for : Schering-Plough,
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationClinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline
Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline Anita Mathias, PhD Clinical Pharmacology, Gilead Sciences 14 th Int. Workshop on Clinical Pharmacology of HIV Therapy April
More informationNS5A inhibitors: ideal candidates for combination?
NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira XR), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationDisclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationHCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD
HCV: The next 18 months David L. Wyles, M.D. Associate Professor of Medicine UCSD FIRST, A LOOK BACK WHAT DID I SAY LAST YEAR? My predictions for genotype 1: Multiple highly efficacious, well-tolerated,
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More information5/10/2016. Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients. HCV life-cycle and antiviral targets
5/1/216 Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients David L. Wyles, MD Associate Professor of Medicine University of California San Diego La Jolla,
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationSTATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD
Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationChronic Hepatitis C Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Chronic Hepatitis C Drug Class Prior Authorization Protocol This policy has been developed through review of medical
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationHepatitis C in 2018: From Evolution to Revolution
Hepatitis C in 218: From Evolution to Revolution Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston, Massachusetts
More informationAASLD/IDSA HCV treatment guidelines. Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School
AASLD/IDSA HCV treatment guidelines Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School Disclosure Statement for Arthur Kim Grant/research support to institution, last 12 months: Gilead
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationHEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA
NEW TREATMENTS FOR HEPATITIS C Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationChronic Hepatitis C Drug Class Monograph
Chronic Hepatitis C Drug Class Monograph Line of Business: Medi-Cal Effective Date: July 10, 2017 (Interim Guidelines; Final Review and Approval by the P&T Subcommittee Pending) This policy has been developed
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: November 14, 2018 Effective Date: January 1, 2019 This drug class prior authorization criteria have been
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationHCV eradication with direct acting antivirals (DAAs)?
HCV eradication with direct acting antivirals (DAAs)? Emilie Estrabaud Service d Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. emilie.estrabaud@inserm.fr HCV eradication with direct
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More informationPopulation Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration
Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration Emi Tafoya, Yasong Lu, Melody Luo, Premkumar Narasimhan, Neelima
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.36 Subject: Daklinza Page: 1 of 8 Last Review Date: March 18, 2016 Daklinza Description Daklinza (daclatasvir)
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationTreating Hepatitis C Virus (HCV) Infection
Slide 1 of 42 Treating Hepatitis C Virus (HCV) Infection Susanna Naggie, MD, MHS Associate Professor of Medicine Duke Clinical Research Institute Durham, North Carolina Slide 3 of 42 Learning Objectives
More informationAntivirals for the treatment of chronic HCV infection: Bench to Bedside and beyond
Antivirals for the treatment of chronic HCV infection: Bench to Bedside and beyond Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures for
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationOvercoming barriers to access to hepatitis C treatment in a rapidly changing landscape
Overcoming barriers to access to hepatitis C treatment in a rapidly changing landscape HIV/AIDS Department and Global Hepatitis Programme Dr. Stefan Wiktor Outline Global Hepatitis Strategy New HCV treatment
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More information